BD to Showcase Cutting-Edge Innovations at the 7th China International Import Expo Under the Theme 'BD Excellence, for a Healthier Future'

The much-anticipated 7th China International Import Expo (hereinafter referred to as "CIIE") is about to grandly open, asChairman Unit of the Medical Device Professional Committee of the CIIE Exhibition AllianceAs a leading enterprise in the medical technology field, BD Medical has actively participated in the exhibition for many years, gaining widespread attention and acclaim for its outstanding innovation capabilities and profound technical expertise. At this year's CIIE, BD Medical willThemed "Excellence for Future Health," the event features five major themed exhibition areas, showcasing nearly a hundred star innovative medical products, including 15 products unveiled for the first time.

Deng Jianmin, Global Senior Vice President of BD and General Manager of Greater ChinaStated: "2024 marks the 30th anniversary of BD Medical's presence in China. After three decades of deep engagement in China, BD Medical has consistently adhered to the philosophy of 'patient-centered care,' accurately addressing clinical needs and continuously providing stable and cost-effective medical solutions. Since entering China in 1994, BD Medical has delivered hundreds of thousands of innovative products. Through the China International Import Expo (CIIE), a bridge connecting the global market with Chinese opportunities, a link for international exchange and cooperation, and a platform for showcasing innovation and sharing, we..."PreviousMore than 95% of the exhibits are accelerated to market, transforming exhibits into products.This year, we have brought the latest R&D achievements in the field of medical technology, committed to exploring the path of innovation and development in medical technology with peers and partners worldwide. We will continue to lead the new trend in medical technology and share the new opportunities of Chinese-style modernization."Encounter, co-create a new pattern for the medical and health industry."

BD Medical Seventh CIIE Booth Design

At this year's CIIE, BD Medical will focus on the theme "BD Excellence, Superior for Future Health" and comprehensively showcase its innovative medical technology achievements and latest product solutions through five key exhibition areas: "Frontier Life Sciences and In Vitro Diagnostics, Intelligent Monitoring and Smart Healthcare, Surgical Intervention and Cancer Diagnosis and Treatment, Silver Hair Health and Home Care," as well as new product launches. This underscores BD Medical’s commitment to aligning with the high-quality development of China's healthcare industry. Notably, BD Medical has innovatively established the "Silver Hair Health and Home Care" section for the first time, aiming to promote the coordinated progress of Healthy China and economic development, achieving new synchronized prosperity for both.

With the help of "CIIE Express""With this all-new exhibition concept, BD Medical will showcase 15 innovative products making their global debut, China debut, or limited debut at 'hyperspeed' during the 7th CIIE. We look forward to leveraging the powerful spillover effects of the CIIE to accelerate the implementation and transformation of medical technology innovations at 'China speed.' Among these innovations...IncludeOne global premiere, eleven China premieres, one limited premiere, and two preheating new products, coveringPeripheral intervention, specialized surgery, oncology diagnosis, urology, and intensive care, among other fields.

From the rich exhibits displayed this time, we canWe can deeply feel that BD Medical always adheres to the innovative concept of "patient-centeredness" and is committed to using advanced medical technology to address those clinical needs that have not been fully met. It is worth mentioning that BD Medical will bringThe world's first, launched in China3CG PICC Traceable and Locatable Peripherally Inserted Central Catheter, the innovative magnetic navigation technology equipped in this product can help achieve full visualization during PICC catheter placement, making the process easier and more efficient for medical staff, thereby further improving the patient's infusion therapy experience. At the same time,Globally pioneering, first launched in ChinaDisposable Female Urinary Drainage Tray (PUREWICK)^®Female Catheter StickWill also make a significant appearance at the BD Medical booth, dedicated to serving the more than three million people in China who suffer from moderate to severe urinary incontinence or require bed rest due to mobility issues.Female patients with urination difficulties, providing a simple, non-invasive, and more dignified urination solution.

At the forefront of digital and intelligent technology exploration, BD Medical will publicly debut its Intelligent Hemodynamic Monitoring Business Unit for the first time.Brought by the DoorA World's First——Hemodynamic Monitoring System Hemodynamic Monitor. This high-end platform is unparalleled in the industry, capable of simultaneously supporting invasive, minimally invasive, and non-invasive techniques. It is also the first to integrate FDA-approved artificial intelligence technology and HPI hypotension prediction technology, making it suitable for a wide range of clinical environments such as operating room monitoring and intensive care units. Meanwhile, BD Medical will also launchGlobal Premiere, Asian Premiere, China PremiereBD FACSDiscover A8 Imaging Spectral Flow Cytometer, this product, known as the "spectral flow cytometer visible to cells," successfully integrates spectral flow cytometry with imaging technology, opening a new era for flow cytometry.A New Chapter in Technology Visualization.

In addition, BD Medical also introduced several innovative products making their debut in China, including the high-end safety arterial blood collection device designed specifically for the Chinese market — BD PresetTM EclipseTM Flash Arterial Blood Collection Device, and the PAXgene, which is being released for the first time in limited quantities in Chinese hospitals and third-party testing laboratories.^®Eight new products, including whole blood ccfDNA preservation tubes, and two preheated new products. This series of cutting-edge innovations aims to provide Chinese patients with more innovative, comprehensive, and diverse diagnostic and treatment solutions.

In response to the development trend of China's silver economy, BD Medical will establish an immersive "Silver Health and Home Care" scenario-based exhibition area for the first time. This area will meticulously integrate six cutting-edge products, solutions, and service systems covering home care to community healthcare. These innovations not only deeply integrate prevention, treatment, monitoring, and care functions, forming a "combination punch" to protect elderly health, but also bring a more comprehensive and high-quality health service experience to women, men, the elderly, senior patients, and the general public with their high convenience, intelligence, and wearable "high-tech" features.

● The world's first non-invasive and catheter-associated urinary tract infection-reducing PUREWICK^®Female Urinary Catheter Stick, dedicated to improving the quality of home care for female patients with moderate to severe urinary incontinence or those who are bedridden and require assistance with urination.

● Hernia Wearable Device BiShanTuo™ Hernia Support Belt is the first wearable postoperative compression rehabilitation hernia garment for inguinal hernia, jointly launched with clinical experts. It enhances patients' rehabilitation experience through intelligent technology.

● BD Libertas™ Wearable Autoinjector is an innovative patch-based injection system designed to automatically deliver large doses or high-viscosity fixed-dose biologics subcutaneously in home or clinical non-emergency settings, helping patients obtain their required medication dosage accurately in a comfortable and discreet manner.

● BD Sentry™ Disposable Safety Lancet with Multi-Facet Needle Design is specifically designed for home care scenarios such as blood glucose monitoring, ensuring accurate blood sampling while reducing patient pain and infection risk.

● BD innovatively proposed the PICC Maintenance Community concept, centered around the world's first 3CG PICC trackable and locatable peripherally inserted central catheter, which was launched initially in China. Tailored for Chinese patients, BD also developed the "Vascular Access Maintenance Journal" mini-program. These two solutions complement each other, greatly assisting patients in easily understanding and successfully completing regular postoperative chemotherapy maintenance.

● In addition, BD has launched lymphocyte subset (TBNK) testing covering innate immunity, humoral immunity, and cellular immunity through local cooperation in China, providing more precise health assessment and intervention for patients with chronic diseases and the elderly population.

These products not onlySuccessfully extending medical service scenarios from hospitals to communities and homes, with the hope that in the future, innovative medical technologies will empower nursing homes, grassroots hospitals, and home care.MeetContemporary Society“Preparation for Old Age”Service demands, enhancing a new eraElderly PopulationThe quality of life, promoting the coordinated development and synchronized growth of healthy aging and the silver economy.。

At this year's CIIE, BD Medical’s new Intelligent Hemodynamic Monitoring Division (Advanced Patient Monitoring, hereinafter referred to as "APM Division") will make its first public appearance. The division will unveil its globally innovative product — the new version of the Hemodynamic Monitoring System — making a dazzling debut on the CIIE stage.

Intelligentization development is one of the key goals of BD's 2025 strategy. BD has always emphasized technology innovation as the driving force, using digital and intelligent means to promote innovation, improve operational efficiency, and enhance the accessibility of products and services for patients. The addition of the AMP business will significantly advance BD’s global "Connected Care" strategy. Its new advanced monitoring technology not only expands BD’s smart connected care solutions but also integrates APM’s valuable technical experience in patient monitoring into BD’s innovation system.

BD Medical continues to increase its investment in the field of intelligent medical technology, constantly exploring and expanding the application scope of digital and intelligent technologies, with a commitment to the research, development, and launch of innovative products. At the same time, BD Medical will actively respond to the advocacy of the National Healthcare Security Administration by introducing the BD Rowa fully automatic medicine dispensing robot along with its accompanying drug traceability code management solution. The core of this solution lies in "single-box management, full-process traceability," using the dispensing robot to achieve full automation of drug traceability and uploading. It is closely integrated with the traceability code platform, automatically collecting batch numbers and expiration dates of drugs, significantly advancing the automation of traceability code collection.

BD will also host a roundtable forum focusing on "The Overall Next-Generation Flow Cytometry Solution under AI Trends," sincerely inviting multiple industry experts to discuss the future blueprint of medical technology digitalization and intelligence. These intelligent and interconnected care solutions not only significantly improve the efficiency and quality of medical services but also bring unprecedented convenience and comfort to patients' healthcare experiences.

In addition to the seven major new product launch events, BD Medical will also carry out a series of rich booth activities such as cooperation signings and industry guideline releases, comprehensively showcasing its breakthrough achievements in the medical field. BD Medical will join hands with numerous partners to jointly explore the future development direction of medical innovation and work together to build a vibrant medical innovation ecosystem.

BD Always Centers on Patients, committed to enhancing the health and well-being of the Chinese people. During the CIIE, BD MedicalWill be held at the boothBlue Paper on Immunity Data of the Chinese Population2.0" Launch CeremonyIt is worth mentioning that the "Blue Paper on Immune Data of the Chinese Population" is the first comprehensive research report by Chinese scientists on the immune status of the Chinese population, providing a solid scientific basis for the formulation of public health policies and personal health management. The release of the Blue Paper on Immune Data of the Chinese Population 2.0...The initiative will open a new chapter, guiding the public and the industry to pay more attention to and enhance the national immunity level.

As a leading enterprise in the medical device industry, BD Medical not only holds a leading position in the global medical technology field but also plays a pioneering role in the development of the Chinese market. It actively contributes to policy improvement and industry advancement. At this year's CIIE, BD Medical will officially release the "Recommendations for Medical Consumables Access Management." This document consolidates the wisdom and experience of numerous experts from within and outside the industry, aiming to establish a more standardized and efficient management system for medical consumables, promote the rational allocation and utilization of medical resources, and ensure patient safety and healthcare quality.

BD Medical Actively Responds to the National Strategy of "Healthy China 2030," Continuously Deepening Collaborative Innovation Partnerships with Top Universities, Research Institutions, and Authoritative Medical Organizations, Committed to the Ongoing Advancement of Medical Technology. At the Upcoming CIIE, BD Medical Will Grandly Host an Expert Sharing and Discussion Session, Focusing on "How the In-Hospital Application Evaluation System for Hemostatic Materials Can Efficiently Empower the Management of High-Value Consumables Within Hospitals." This In-Hospital Application Evaluation System for Hemostatic Materials, Through Information-Based and Intelligent Management Methods, Not Only Achieves Full-Process Supervision and Rational Allocation of High-Value Consumables but Also Precisely Addresses the Urgent Challenges Currently Faced by Medical Institutions in Managing High-Value Consumables, Meeting the Industry's Demand for Efficient and Precise Management. During the CIIE, BD Medical Will Also Sign a Cooperation Agreement with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, for the Intentional Procurement of Medical Consumables.

During the CIIE, BD Medical will host Fulaixi.^®PosiFlush™ Local Production New Product Launch and Signing Ceremony, BD Medical Peripheral Intervention New Era and Straub Mechanical Thrombectomy System Platform Strategic Signing Ceremony, and BD Medical Single-Cell Multi-Omics Strategic Cooperation Signing Ceremony. These events not only demonstrated BD Medical's strong capabilities in the field of medical device innovation but also reflected its deep cooperation with local governments and partners in new product development, technology introduction, industrial chain platform construction, and supply chain management. By continuously deepening its localization strategy, BD Medical stimulates the innovative vitality and production potential of locally produced medical devices, accelerates collaboration with China's medical industry, and injects strong momentum into the vigorous development of China's healthcare market.

As a leader in the medical device industry, BD demonstrates its commitment to leading industry development by fully leveraging its unique advantages in localized innovation and actively strengthening in-depth communication and close cooperation with multiple stakeholders, including industry, academia, research, and healthcare. During this year's CIIE, the first documentary on the development of hernia surgery in China, *Legend*, will also hold its release ceremony at the BD booth. This event not only highlights BD's firm commitment to advancing the field of hernia surgery in China but also reflects its dedication to driving industry openness, innovation, and transformation through new technologies, scenarios, materials, designs, and channels. BD is committed to building a collaborative and win-win medical device ecosystem while working with all parties to create an innovation-driven healthcare ecosystem.

As the CIIE approaches, BD will join hands with global partners to fulfill this win-win and future-oriented commitment. BD not only continues to value the "China opportunity" presented by the CIIE as a top international economic and trade exchange platform, but will also witness alongside China's medical technology industry—and deeply engage in—the vivid practice of "exhibits turning into products and being implemented nationwide," further strengthening its "symbiotic" relationship with China's medical industry and propelling the innovative forces of China’s healthcare sector onto the international stage.

BD is a global medical technology company that leads in world health by improving methods of medical discovery, enhancing diagnostic outcomes, and advancing the quality of care. BD supports every frontline healthcare worker with a focus on innovation, offering advanced technologies, services, and solutions to improve clinical treatment for patients and optimize clinical processes for healthcare providers. With 75,000 employees worldwide, BD operates with passion and purpose to deliver safe and efficient medication delivery systems for clinicians, empower laboratory scientists to diagnose diseases more effectively, and enhance researchers' ability to develop next-generation diagnostics and therapies. BD has branches in nearly every country and actively collaborates with organizations globally to address the most pressing health challenges. By working closely with customers, BD is committed to improving treatment outcomes, reducing healthcare costs, and increasing diagnostic efficiency, while strengthening the safety of patients and healthcare workers and expanding access to healthcare.